孟立锋 向彩春 杨端云 陶志虎 覃志周 农邵阳
(广西中药大学第一附属医院,广西 南宁,530023)
中图分类号:R289.6 文献标识码:A 文章编号:1674-7860(2016)12-0018-03 证型:IDGB
【摘 要】目的:探讨加味六君子汤对腹膜纤维化大鼠TGF-β/Smad信号通路的影响。方法:用5/6肾切除联合腹腔注射4.25%腹透液+脂多糖(LPS)建立腹膜纤维化大鼠模型,实验分空白组(A组)、模型组(B组)、西药组(C组)、中药高剂量组(D组)、中药低剂量组(E组),Western印迹法检测TGF-β1、p-Smad2/3、Smad7和α-SMA、E-cadherin蛋白的表达:RT-PCR法测定TGF-β1、α-SMA、E-cadherinmRNA水平。结果:与A组相比,B组、C组、D组、E组TGF-β1、p-Smad2/3、α-SMA蛋白和α-SMAmRNA表达水平升高,有显著性差异(P<0.05);与B组相比,C组、D组、E组TGF-β1、p-Smad2/3、α-SMA蛋白和α-SMAmRNA表达水平降低,Smad7和E-cadherin蛋白和E-cadherinmRNA表达水平增高,有显著性差异(P<0.05)。结论:加味六君子汤可能通过TGF-β/Smad信号通路,抑制腹膜间皮细胞EMT进程,进而起到一定拮抗腹膜纤维化作用。
【关键词】腹膜纤维化;TGF-β/Smad信号通路;腹膜间皮细胞间充质转化;加味六君子汤
【Abstract】Objective: Toinvestigate the effect of Modified Liujunzi decoction on TGF-β/Smad singnal pathway of peritonealfibrosis rat model. Methods: The peritoneal fibrosis rat model was establishedby 4.25% dialysate and lipopoly saccharide (LPS) based on five sixthsnephrectomy.The rats were randomly divided into controlgroup (A),peritoneal fibrosis model group (B), westernmedicine group (C), high dose Modified Liujunzi decoction treating group (D),low dose Modified Liujunzi decoction treating group (E).The expression of TGF-β1, p-Smad2/3, Smad7, α-SMA and E-cadherin protein inperitoneal membrane was detected with Western blotting, the level of TGF-β1,α-SMA and E-cadherin mRNA was detected by using real-time polymerase chain reaction (RT-PCR).Results:After treatment, compared with group A, the expressionof TGF-β1, p-Smad2/3,α-SMA protein andα-SMAmRNA in groupB, C, D and E was up-regulated,and the difference was statistically significant (P<0.05).Compared with group B, the expression of TGF-β1, p-Smad2/3, α-SMA protein andα-SMAmRNA in group C,D and E decreased while the expression of Smad7,E-cadherin protein and E-cadherin mRNA increased, and the difference was statistically significant (P<0.05). Conclusion: Modified Liujunzi decoction could preventor reduce the incidence and progression of epithelial-to-mesenchymal transitionin peritoneal fibrosis through TGF-β/Smadsingnal pathway, which in turn exerted a certain antagonism of peritoneal fibrosis.
【Keywords】Peritonealfibrosis; TGF-β/Smad singnal pathway;Epithelial-to-mesenchymal transition; Modified Liujunzi decoction
doi:10.3969/j.issn.1674-7860.2016.12.009
[1]Leung JC,Chan LY,Tang SC,et al.Leptininduces TGF-beta synthesis through functional leptin receptor expressed byhuman peritoneal mesothelial cell[J].Kidney Int,2006,69(11):2078-2086.
[2]孟立锋.史伟.从痰瘀互结论腹膜纤维化的病因病机[J].新中医.2012,44(08):200-201.
[3]聂振禹,陈争跃,包蓓艳.一种改良的尿毒症腹膜透析大鼠模型[J].中国病理生理杂志,2013,29(11):2109-2122.
[4]陈刚毅,苏保林,孟立锋,等.化痰祛瘀法对腹膜纤维化大鼠腹膜致密层厚度及SMA、E-cadherin蛋白表达的影响[J].湖南中医杂志,2011,27(05):126-127.
[5]Li JH,ZhuHJ,HuangXR,etal.Smad7 inhibits fibrotic effect of TGF-beta on renal tubular epithelial cellsby blocking Smad2 activation[J].JAmSocNephrol,2002(13):1464.
[6]Jesu´s Loureiro,Abelardo Aguilera,RafaelSelgas,et al.Blocking TGF-β1protects the peritoneal membrane from dialysate-induced damage[J].KidneyInt,2006,69(11):2078-2086.
[7]Aroeira LS ,Aguilera A,Sanchez-Tomero JA,et al.Epithelial to mesenchymal transition and peritoneal membrane failure inperitoneal dialysis patients: pathologic significance and potential therapeuticinterventions[J].J Am Soc Nephrol,2007,18(7):2004-2013.
[8]Zeisberg M,Neilson E G. Biomarkers forepithelial-mesenchymal transitions[J].J Clin Invest.,2009,119(6): 1429-1437.
[9]孟立锋,谢永祥,陶志虎,等.健脾化痰祛瘀方防治腹透患者腹膜纤维化60例临床研究[J].中医临床研究,2015,7(30):70-73.